We are live on ! Find out more
LSBPW

LakeShore Biopharma Warrants
LSBPW

Delisted

LSBPW was delisted on the 19th of September, 2025.

Back to rankings

18 hedge funds and large institutions have $381K invested in LakeShore Biopharma Warrants in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $346K → $381K (+$34.4K)

0.13% more ownership

Funds ownership: 2.05% → 2.18% (+0.13%)

14% less funds holding

Funds holding: 21 → 18 (-3)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
18
Holders Change
-3
Holders Change %
-14.29%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
3
Calls
$40K
Puts
–
Net Calls
+$40K
Net Calls Change
-$35K

Top Buyers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
+$54.1K

Top Sellers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
-$1.65K
2
TSS
Two Sigma Securities
New York
-$1.15K
3
Walleye Capital
Walleye Capital
New York
-$251
Name Holding Trade Value Shares
Change 		Change in
Stake
LP
1
LMR Partners
United Kingdom
$83.6K +$54.1K +1,052,461 New
VAM
2
Valliance Asset Management
Hong Kong
$59.5K – – –
FC
3
Finepoint Capital
Massachusetts
$48.5K – – –
AC
4
Athos Capital
Hong Kong
$45K – – –
Jane Street
5
Jane Street
New York
$39.6K – – –
BCL
6
Bracebridge Capital LLC
Massachusetts
$18.4K – – –
OCM
7
Ovata Capital Management
Hong Kong
$14.8K – – –
Calamos Advisors
8
Calamos Advisors
Illinois
$14.5K – – –
QGA
9
Q Global Advisors
Texas
$10K – – –
WA
10
Whitebox Advisors
Minnesota
$9.93K – – –
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$9.9K – – –
SCM
12
Saba Capital Management
New York
$7.73K – – –
Walleye Capital
13
Walleye Capital
New York
$7.54K -$251 -4,875 -5%
CF
14
Cantor Fitzgerald
New York
$6.15K – – –
CS
15
Clear Street
New York
$3.83K – – –
SIA
16
SkyView Investment Advisors
New Jersey
$1K – – –
AA
17
Ancora Advisors
Ohio
$401 – – –
HIM
18
HGC Investment Management
Ontario, Canada
$397 – – –
CAC
19
Cowen and Company
New York
– -$14.1K -212,849 Closed
MC
20
Meteora Capital
Florida
– -$1.65K -25,000 Closed
TSS
21
Two Sigma Securities
New York
– -$1.15K -17,400 Closed

LSBPW Hedge Fund Activity: Q4 2024 in Review

18 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q4 2024, worth a combined $381K — up 9.9% from $346K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LSBPW and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was LMR Partners, opening a new position worth an estimated $54.1K. The largest seller was Meteora Capital, exiting entirely with an estimated $1.65K sold.

  • 18 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q4 2024, down from 21 in Q3 2024.
  • Funds reported $381K of LakeShore Biopharma Warrants stock for Q4 2024, up 9.9% quarter-over-quarter.
  • 1 fund opened new LakeShore Biopharma Warrants positions in Q4 2024 and 3 closed out, a net change of -2 holders.
  • The largest LakeShore Biopharma Warrants buyer in Q4 2024 was LMR Partners, an estimated $54.1K added.
  • The largest LakeShore Biopharma Warrants seller in Q4 2024 was Meteora Capital, an estimated $1.65K sold.

Based on aggregated 13F filings for Q4 2024.